- Poster presentation
- Open Access
Co-immunization with HIV Env DNA and protein elicit long-lasting strong cellular and humoral immune responses
© Li et al; licensee BioMed Central Ltd. 2012
- Published: 13 September 2012
- Humoral Immune Response
- Rhesus Macaque
- High Viremia
- Vaccine Platform
- Inactivate Virus Particle
We have previously reported that potent, long-lasting HIV-1 Env-specific cell-mediated immune responses could be elicited in rhesus macaques and mice using plasmids encoding env DNA as the immunogen. Subsequent experiments showed that combination of DNA and protein in the form of inactivated virus particles provided significant protection from infection and high viremia. We examine a vaccine platform combining DNA and recombinant Env protein co-immunization at the same time to generate both strong cellular and humoral immune responses.
Mice or macaques were immunized with HIV env gp120 DNA vaccine and/or purified gp120 protein from clade B or clade C isolates. Mice were immunized twice at 4 weeks interval with DNA only, protein only formulated in EM005 adjuvant, or DNA&protein/EM005. Macaques were immunized twice at 4 weeks interval with DNA only, DNA&protein, DNA&protein/EM005.
DNA&protein co-immunization enhances the Ab responses compared with DNA or protein only in mice. DNA&protein co-immunization generated similar levels of cellular immune responses compared to mice immunized with DNA only but those levels were significantly higher than those obtained in mice immunized with protein only. The establishment of a mouse model that gives similar results with the macaque model enhances our ability to test many variations and optimize the vaccine. Importantly, in macaques this strategy elicited higher binding and neutralizing Ab responses than DNA only and the neutralizing Abs showed broad activity. The presence of the EM005 adjuvant further enhanced the Ab responses. These responses were correlated with the up-regulated activation of dendritic cells by EM005. The longevity of the Ab response was superior.
The strategy of DNA and protein co-immunization has potential for development as a prophylactic HIV-1 vaccine. Our challenge studies show that DNA and protein co-immunized animals developing long-lasting Ab titers were protected from infection.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.